Solid tumor oncology clinical trials commonly use transcriptomics instead of measuring specific protein biomarkers for a few reasons. First, transcriptomics provides a more comprehensive view of the changes happening at the gene level in response to a treatment. This can give researchers a better understanding of how a treatment is affecting the tumor and whether it is working. Additionally, transcriptomics is less expensive and more accessible than protein biomarker testing.